La cadena de opciones muestra datos clave de las opciones de acciones de Ferrovial a varios precios de ejercicio y fechas de vencimiento. Los operadores utilizan esta información para analizar posibles operaciones y evaluar el sentimiento del mercado para Ferrovial..

Ferrovial (NASDAQ:FER) Bolsa, Cadena de Opciones

Ferrovial SE is a Spanish industrial company. The company organizes itself into four segments: Toll Roads, Airports, Construction, and Energy. The Toll Roads segment develops and operates toll roads globally. The Airports segment includes the Development, financing and operation of airports. The Construction segment Designs and executes all public and private works, including most notably the construction of public infrastructures. The Energy segment focuses on innovative solutions for promoting, constructing and operating energy generation and transmission infrastructures.

ACXIF

ANYYY

BBVA

BKNIY

CAIXY

GASNY

GRFS

Internationalnsolidated Airlines Group Sponsored American Depository Receipt

ICAGY

SYRVF

Las políticas económicas de Trump están sacudiendo el IBEX 35. Empresas españolas enfrentan incertidumbre, aranceles y cambios regulatorios.

Cómo las nuevas políticas de Trump están afectando a las empresas del IBEX 35

AAPL

ACSAY

AMZN

MRPRF

MSFT

ACS, Ferrovial y MERLIN Properties están transformando el sector de centros de datos en España con inversiones clave y alianzas estratégicas.

Tres acciones del Ibex 35 que lideran el sector de centros de datos en 2024

Ferrovial SE

Fifth Era Acquisition Corp I

Ferguson Enterprises Inc

Fearless Films Inc

Fernhill Corp

WIIM

MRVL

Marvell Technology shares are trading lower following roughly in-line guidance.

MongoDB shares are trading lower following weak guidance.

Clearside Biomedical, Inc.&nbsp;(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CLSD#NASDAQ">CLSD</a>) ("Clearside" or the "Company"), a biopharmaceutical company revolutionizing the delivery of therapies to the back of the eye through the suprachoroidal space (SCS&#xAE;), announced today the receipt of the formal meeting minutes from its recent End-of-Phase 2 meeting with the U.S. Food and Drug Administration (FDA) relating to CLS-AX (axitinib injectable suspension) for the treatment of neovascular age-related macular degeneration (wet AMD). CLS-AX combines the flexible dosing of a biologic with the longer duration of a tyrosine kinase inhibitor (TKI) and is administered via suprachoroidal injection utilizing Clearside's patented SCS Microinjector&#xAE;.

Government

News

Regulations

CLSD

Clearside Biomedical Advances Wet AMD Treatment, Receives FDA End-of-Phase 2 Meeting Minutes for CLS-AX

On Thursday, <a target="_blank" href="https://www.benzinga.com/topic/alibaba" rel="noreferrer noopener">Chinese e-commerce juggernaut</a> Alibaba Group&nbsp;Holding (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BABA#NYSE">BABA</a>) launched a new reasoning model comparable to that of its affordable rival DeepSeek&#8217;s R1, Reuters reports.
Alibaba Qwen artificial intelligence unit <a target="_blank" href="https://x.com/alibaba_qwen?lang=bg" rel="noreferrer noopener">tweeted</a> that its QwQ-32B, with 32 billion parameters, can achieve performance comparable to DeepSeek&#8217;s R1 model.
On Wednesday, China&nbsp;pledged&nbsp;increased support for industries including AI, humanoid robots, and 6G telecom, as AI models noted growing adoption by government agencies and smaller companies in China.
Also Read: <a target="_blank" href="https://www.benzinga.com/25/03/44147370/taiwan-semiconductor-caught-between-us-tariff-threats-and-taiwans-push-to-keep-advanced-chip-tech" rel="noreferrer noopener">Taiwan Semiconductor Caught Between US Tariff Threats and Taiwan&#8217;s Push To Keep Advanced Chip Tech</a>
Alibaba said the new model is accessible via its chatbot service, Qwen Chat. Users can choose various Qwen models and demonstrate mathematical reasoning, coding, and general problem-solving capabilities in benchmark tests.
Analysts told Reuters that government initiatives will expand usage of AI in China.
Beijing plans to <a target="_blank" href="https://www.benzinga.com/25/03/44158266/alibaba-jumps-7-on-deepseek-rival-launch-as-china-pledges-to-vigorously-boost-consumption-hang-seng-hits-2-year-high" rel="noreferrer noopener">issue 1.3 trillion yuan ($179 billion)</a> in ultra-long special treasury bonds in 2025, up from 1 trillion yuan in 2024. It will allow local governments to issue 4.4 trillion yuan in special debt. The budget deficit will likely widen to around 4% of GDP.
Alibaba was among the first major global tech companies to <a target="_blank" href="https://www.benzinga.com/25/02/44040003/alibaba-expands-ai-workforce-while-deepseek-slashes-model-prices-in-market-battle" rel="noreferrer noopener">open-source its large-scale AI models</a>.
Alibaba&nbsp;committed&nbsp;$53 billion&nbsp;to <a target="_blank" href="https://www.benzinga.com/media/25/02/43939199/alibaba-doubles-down-on-ai-launches-qwq-max-to-challenge-openai-and-deepseek" rel="noreferrer noopener">cloud and AI infrastructure</a> over the next three years.
DeepSeek&#8217;s&nbsp;AI model price war offers developers discounted off-peak pricing. Chinese tech companies like&nbsp;Alibaba and its rivals were already&nbsp;engaged in a price war&nbsp;to win market share.&nbsp;
Benchmark&#8217;s&nbsp;Fawne Jiang hailed Alibaba as a leading player in&nbsp;China&#8217;s AI sector, backed by its edge in infrastructure, proprietary models, and application capacity across diverse use cases.
Price Action:&nbsp;BABA stock closed higher by 8.61% at $141.03 on&nbsp;Wednesday.
Also Read:
<ul>
<li><a href="https://www.benzinga.com/25/03/44143705/applovin-reportedly-selling-gaming-unit-to-tripledot-studios-in-900-million-deal" target="_blank" rel="noreferrer noopener">Applovin Reportedly Selling Gaming Unit To Tripledot Studios In $900-Million Deal</a></li>
</ul>
Photo by jackpress via Shutterstock

Asia

Emerging Markets

Tech

Media

BABA

Alibaba Expands AI Push With New QwQ-32B Model Taking on DeepSeek In China's AI Race

Biotech

Earnings

Guidance

Health Care

General

XERS

Xeris Biopharma Expects 2025 Revenue Of $255M-$275M, Representing Growth Of Over 30% At The Mid-point Of The Range Versus Consensus Of $239.84M

Superior Industries Intl (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SUP#NYSE">SUP</a>) reported quarterly losses of $(0.75) per share which beat the analyst consensus estimate of $(0.91) by 17.58 percent. This is a 70.45 percent decrease over losses of $(0.44) per share from the same period last year. The company reported quarterly sales of $310.300 million which missed the analyst consensus estimate of $333.000 million by 6.82 percent. This is a 0.55 percent increase over sales of $308.600 million the same period last year.

Earnings Beats

Earnings Misses

Superior Industries Intl Q4 2024 GAAP EPS $(0.75) Beats $(0.91) Estimate, Sales $310.300M Miss $333.000M Estimate

Rosenblatt analyst Catharine Trebnick upgrades Zscaler (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ZS#NASDAQ">ZS</a>) from Neutral to Buy and raises the price target from $190 to $235.

Upgrades

Price Target

Analyst Ratings

Rosenblatt Upgrades Zscaler to Buy, Raises Price Target to $235

TRNR

Interactive Strength Signs Letter Of Intent And Exclusivity Agreement To Acquire A Connected-Fitness Equipment Business That Earned Over $15M In Revenue In 2024; Acquired Through All-Stock Consideration, Says It Expects To Improve The Target's Profitability Through Potential Operating Synergies

Reaffirms Full Year 2025 Outlook
<figure class="table"> 
<table>
<tbody>
<tr>
<td colspan="1" rowspan="1">Global systemwide sales growth</td>
<td colspan="1" rowspan="1">2 to 3 percent</td>
</tr>
<tr>
<td colspan="1" rowspan="1">Adj. earnings per share</td>
<td colspan="1" rowspan="1">$0.98 to $1.02</td>
</tr>
<tr>
<td colspan="1" rowspan="1">Adj. EBITDA</td>
<td colspan="1" rowspan="1">$550 to $560 million</td>
</tr>
<tr>
<td colspan="1" rowspan="1">Capital expenditures</td>
<td colspan="1" rowspan="1">$100 to $110 million</td>
</tr>
<tr>
<td colspan="1" rowspan="1">Free cash flow</td>
<td colspan="1" rowspan="1">$275 to $285 million</td>
</tr>
</tbody>
</table>
</figure>

Wendy's Reaffirms 2025 Outlook, Global Systemwide Sales Growth Of 2% - 3%,
Adj EPS Of $0.98 - $1.02 (Est $1.02)

GWRS

Reported Earlier, Global Water Resources FY 2024 Adj. EPS $0.26 Misses $0.28 Estimate, Sales $52.692M Beat $52.400M Estimate

Marex Group (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MRX#NASDAQ">MRX</a>) reported quarterly earnings of $0.76 per share which beat the analyst consensus estimate of $0.64 by 18.75 percent. This is a 40.74 percent increase over earnings of $0.54 per share from the same period last year. The company reported quarterly sales of $415.60 million which beat the analyst consensus estimate of $378.44 million by 9.82 percent. This is a 27.64 percent increase over sales of $325.60 million the same period last year.

Marex Group Q4 Adj EPS $0.76 Beats $0.64 Estimate, Revenue $415.60M Beat $378.44M Estimate

Mind Medicine (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MNMD#NASDAQ">MNMD</a>) reported quarterly losses of $(0.41) per share which missed the analyst consensus estimate of $(0.30) by 36.67 percent. This is a 30.51 percent increase over losses of $(0.59) per share from the same period last year.

MNMD

Mind Medicine Q4 2024 GAAP EPS $(0.41) Misses $(0.30) Estimate, Cash And Cash Equivalents Of $273.7M As Of December 31, 2024, Expected To Fund Operations Into 2027 And Extend At Least 12 Months Beyond The First Phase 3 Topline Data Readout For MM120 Orally Disintegrating Tablet In Generalized Anxiety Disorder

BlackSky Technology Inc. Class A Common Stock

BKSY

BlackSky Sees 2025 Revenue Of $125M-$142M (Vs. Cons. Of $133.648M), Adjusted EBITDA Of $14M-$22M

Macy's shares are trading lower following weak FY25 guidance.

Wendy's Reveals Long-term Financial Algorithm Of 3-4% Annual Net Unit Growth, 5-6% Annual Systemwide Sales Growth, And 7-8% Annual Adjusted EBITDA Growth

Real Brokerage (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/REAX#NASDAQ">REAX</a>) reported quarterly losses of $(0.03) per share which beat the analyst consensus estimate of $(0.04) by 25 percent. This is a 57.14 percent increase over losses of $(0.07) per share from the same period last year. The company reported quarterly sales of $350.63 million which beat the analyst consensus estimate of $300.11 million by 16.83 percent. This is a 93.35 percent increase over sales of $181.34 million the same period last year.

REAX

Real Brokerage Q4 GAAP EPS $(0.03) Beats $(0.04) Estimate, Sales $350.63M Beat $300.11M Estimate

Needham analyst Quinn Bolton reiterates Rigetti Computing (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RGTI#NASDAQ">RGTI</a>) with a Buy and maintains $17 price target.

Reiteration

RGTI

Needham Reiterates Buy on Rigetti Computing, Maintains $17 Price Target

Wendy's To Host Its 2025 Investor Day Today; Outlines Expectations To Add 1,000 Net New Restaurants Globally By 2028

Xeris Biopharma Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/XERS#NASDAQ">XERS</a>) reported quarterly losses of $(0.03) per share which beat the analyst consensus estimate of $(0.06) by 50 percent. This is a 70 percent increase over losses of $(0.10) per share from the same period last year. The company reported quarterly sales of $60.10 million which beat the analyst consensus estimate of $58.10 million by 3.43 percent. This is a 35.39 percent increase over sales of $44.39 million the same period last year.

Xeris Biopharma Holdings Q4 2024 GAAP EPS $(0.03) Beats $(0.06) Estimate, Sales $60.10M Beat $58.10M Estimate

BlackSky Technology (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BKSY#NYSE">BKSY</a>) reported quarterly losses of $(1.01) per share which missed the analyst consensus estimate of $(0.31) by 225.81 percent. This is a 320.83 percent decrease over losses of $(0.24) per share from the same period last year. The company reported quarterly sales of $30.37 million which missed the analyst consensus estimate of $34.22 million by 11.26 percent. This is a 14.47 percent decrease over sales of $35.51 million the same period last year.

BlackSky Technology Q4 2024 GAAP EPS $(1.01) Misses $(0.31) Estimate, Sales $30.37M Miss $34.22M Estimate

Press Releases

Frank Raha joins Ferrovial's Cintra to lead U.S. public affairs

Commodities

Ferrovial appoints Pepe Baraja to lead its construction division for the U.S. and Canada

Ferrovial reached $447 million net profit in the first half of the year

10 Years of Progress: How the TEXpress Lanes are Shaping the Future of Infrastructure and Growth

Ferrovial increased adjusted EBITDA by 50% in the first nine months of the year

András Szakonyi named CEO of Ferrovial's Digital Infrastructure Division

Ferrovial closes the sale of a 19.75% stake in Heathrow for 2,000 million euros

Ferrovial recognized as a sustainability leader in Dow Jones Sustainability Index World

Comments

Ferrovial

Ferrovial (FER) Opciones

No option chain data available. Please try again later

Noticias

SOCIO/CONTRIBUIDOR

BENZINGA GLOBAL